Review
Gastroenterology & Hepatology
Uma Mahadevan, Saule Naureckas, Ilia Tikhonov, Yiting Wang, Connie B. Lin, Anja Geldhof, C. Janneke van der Woude
Summary: This study evaluated the pregnancy outcomes of patients exposed to ustekinumab during pregnancy. The results showed that the rates of adverse pregnancy outcomes or congenital anomalies with ustekinumab exposure were similar to those reported for the general population in the US, indicating no increased risk associated with maternal or paternal exposure to ustekinumab.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Dermatology
R. B. Warren, M. Lebwohl, H. Sofen, V. Piguet, M. Augustin, F. Brock, C. Arendt, F. Fierens, A. Blauvelt
Summary: The study reports 3-year outcomes from the CIMPACT phase 3 trial, showing durable response to CZP in moderate to severe plaque psoriasis without identification of new safety signals.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Dermatology
Yoshinori Umezawa, Akihiko Asahina, Shinichi Imafuku, Yayoi Tada, Shigetoshi Sano, Akimichi Morita, Shinya Sakurai, Naoki Hoshii, Nicola Tilt, Hidemi Nakagawa
Summary: The study showed that treatment with Certolizumab pegol (CZP) can improve symptoms of psoriasis in patients, and this improvement can be maintained for up to 52 weeks. The 400 mg every 2 weeks dose may provide additional clinical benefits.
DERMATOLOGY AND THERAPY
(2021)
Review
Pharmacology & Pharmacy
Laura Saint-Lary, Alpha Diallo, Laure-Amelie de Monteynard, Christelle Paul, Lucie Marchand, Roland Tubiana, Josiane Warszawski, Laurent Mandelbrot, Claire Rekacewicz, Ventzislava Petrov-Sanchez, Albert Faye, Jeanne Sibiude, Francois Dabis, Agnes Sommet, Valeriane Leroy
Summary: The study found that the use of protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) based regimens did not show significant association with adverse pregnancy outcomes, except for nucleoside reverse transcriptase inhibitor (NRTI) combinations. The number of integrase inhibitor (INI)-based combinations was too low to draw conclusions from.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Rheumatology
Desiree van der Heijde, Lianne S. Gensler, Walter P. Maksymowych, Robert Landewe, Martin Rudwaleit, Lars Bauer, Thomas Kumke, Mindy Kim, Simone Emanuele Auteri, Bengt Hoepken, Atul Deodhar
Summary: The 52-week results from the C-axSpAnd study demonstrate the long-term safety and efficacy of Certolizumab pegol (CZP) in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). CZP treatment for up to 3 years is well tolerated and leads to sustained clinical improvement.
Article
Immunology
Nils Venhoff, Jens Thiel, Markus A. Schramm, Ilona Jandova, Reinhard E. Voll, Cornelia Glaser
Summary: Limited treatment options are available for pregnant patients with Cogan's syndrome due to potential fetal toxicity. Certolizumab pegol is considered safe for pregnant patients with underlying inflammatory diseases, but there is currently a lack of literature on its use in Cogan's syndrome patients, especially during pregnancy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Dermatology
Yukari Okubo, Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa
Summary: This study reports the efficacy and safety of certolizumab pegol (CZP) in Japanese patients with generalized pustular psoriasis (GPP) and erythrodermic psoriasis (EP). The results showed that CZP treatment improved the signs and symptoms of GPP and EP, and the improvements were maintained throughout the treatment period.
DERMATOLOGY AND THERAPY
(2022)
Article
Rheumatology
Chak Sing Lau, Yi-Hsing Chen, Keith Lim, Marc de Longueville, Catherine Arendt, Kevin Winthrop
Summary: The study evaluated the incidence rates of TB and HBV/HCV during CZP treatment, showing that the risks are relatively low, especially in the Asia-Pacific region.
CLINICAL RHEUMATOLOGY
(2021)
Article
Rheumatology
D. Prieto-Pena, M. Calderon-Goercke, A. Adan, L. Chamorro-Lopez, O. Maiz-Alonso, J. R. De Dios-Jimenez Aberasturi, R. Veroz, S. Blanco, J. M. Martin-Santos, F. Navarro, A. Gallego, S. Gonzalez-Suarez, A. Conesa, A. Garcia-Valle, M. Cordero-Coma, N. Pardinas-Baron, R. Demetrio, V Calvo-Rio, V. M. Martinez-Taboada, S. Castaneda, J. L. Hernandez, M. A. Gonzalez-Gay, R. Blanco
Summary: The study found that CZP is safe and effective in pregnant women with uveitis. There were no significant risks of infection or malformations for mothers and infants exposed to CZP during pregnancy.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)
Article
Rheumatology
Xenofon Baraliakos, Torsten Witte, Luc De Clerck, Bruno Frediani, Eduardo Collantes-Estevez, Gkikas Katsifis, Brenda VanLunen, Elisabeth Kleine, Bengt Hoepken, Lars Bauer, Nicola Goodson
Summary: This study found that the efficacy and safety of certolizumab pegol (CZP) in patients with axial spondyloarthritis (axSpA) in European clinical practice were similar to those from previous randomized clinical trials.
Article
Immunology
Annamaria Mascolo, Gabriella di Mauro, Federica Fraenza, Mario Gaio, Alessia Zinzi, Ciro Pentella, Francesco Rossi, Annalisa Capuano, Liberata Sportiello
Summary: Although the scientific evidence supporting the use of COVID-19 vaccines during pregnancy is limited, this study suggests that the benefits of COVID-19 vaccines during pregnancy outweigh the possible risks. Monitoring the safety profile of COVID-19 vaccines in pregnant women is important.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
A. Saraux, B. Combe, F. Fagnani, G. Cukierman, I Bru, J-M Joubert, J-C Schuller, J. Massol, R-M Flipo
Summary: The prospective, observational study in France on the long-term effectiveness and safety of certolizumab pegol in patients with moderate-to-severe rheumatoid arthritis confirms the drug's efficacy and safety profile in real-world settings.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Imran Shahid, Alvin Joseph, Eric Lancelot
Summary: This study evaluated the importance of symptoms associated with gadolinium exposure in the overall population and found significant differences in the weight of these symptoms among different gadolinium-based contrast agents (GBCAs). It suggested that linear GBCAs may be more likely to cause symptoms than macrocyclic contrast agents, and that gadoteridol may have a higher risk of symptoms compared to other macrocyclic GBCAs.
INVESTIGATIVE RADIOLOGY
(2022)
Article
Pharmacology & Pharmacy
R. L. Bromley, M. Bickle Graz, M. Bluett-Duncan, C. Chambers, P. Damkier, K. Dietrich, H. Dolk, K. Grant, S. Mattson, K. J. Meador, H. Nordeng, T. F. Oberlander, A. Ornoy, A. Revet, J. Richardson, J. Rovet, L. Schuler-Faccini, E. Smearman, V. Simms, C. Vorhees, K. Wide, A. Wood, L. Yates, E. Ystrom, T. A. Supraja, J. Adams
Summary: The study aims to achieve consensus on the core neurodevelopmental outcomes, optimize methodologies, and overcome barriers in conducting pregnancy pharmacovigilance studies with neurodevelopmental outcomes. The vision is to establish a comprehensive understanding of neurodevelopmental outcomes in pregnancy pharmacovigilance through a complementary set of studies.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Psychiatry
Diane Merino, Alexandre Olivier Gerard, Alexandre Destere, Florence Askenazy, Emmanuelle Dor, Michel Benoit, Faredj Cherikh, Milou-Daniel Drici
Summary: This study investigates the potential triggers for eating disorders, specifically anorexia nervosa (AN) and bulimia nervosa (BN). Using real-world data from the WHO safety database, the study finds a correlation between certain drugs such as isotretinoin, lamivudine, nevirapine, and zidovudine, and the development or relapse of AN and BN. It suggests that mental health conditions should be assessed before treatment initiation to identify patients at risk.
PSYCHIATRY RESEARCH
(2023)
Article
Rheumatology
Christina D. Chambers, Diana L. Johnson, Ronghui Xu, Yunjun Luo, Robert Felix, Minh Fine, Chloe Lessard, Margaret P. Adam, Stephen R. Braddock, Luther K. Robinson, Leah Burke, Kenneth Lyons Jones
Summary: This study found no evidence of an increased risk of structural birth defects or other adverse outcomes among women receiving hydroxychloroquine (HCQ) treatment during pregnancy, except for infant head circumference at birth.
ARTHRITIS & RHEUMATOLOGY
(2022)
Article
Substance Abuse
Natasia S. Courchesne-Krak, Maria Luisa Zuniga, Christina Chambers, Mark B. Reed, Laramie R. Smith, Jerasimos Ballas, Carla Marienfeld
Summary: This study examined the relationship between substance-related diagnoses and the likelihood of preterm and cesarean delivery in pregnant women. The findings showed that pregnant women with a substance-related diagnosis were more likely to have preterm and cesarean delivery compared to those without such a diagnosis. The type of substance-related diagnosis also predicted the occurrence of co-occurring preterm and cesarean delivery.
JOURNAL OF ADDICTIVE DISEASES
(2023)
Article
Pediatrics
Kefeng Li, Kerri Bertrand, Jane C. Naviaux, Jonathan M. Monk, Alan Wells, Lin Wang, Sai Sachin Lingampelly, Robert K. Naviaux, Christina Chambers
Summary: The chemical analysis of human milk can predict the risk of neurodevelopmental delay in infants, allowing for early interventions before symptoms appear.
PEDIATRIC RESEARCH
(2023)
Review
Pharmacology & Pharmacy
Sydney P. Thomas, Erce Denizer, Simone Zuffa, Brookie M. Best, Lars Bode, Christina D. Chambers, Pieter C. Dorrestein, George Y. Liu, Jeremiah D. Momper, Victor Nizet, Shirley M. Tsunoda, Adriana H. Tremoulet
Summary: Antibiotics are crucial for perinatal care, but they can harm the host gut microbiota. Current studies mainly focus on the effects of antibiotics on infants directly or through maternal use, with limited knowledge about the risks of antibiotics in human milk to infants.
Article
Substance Abuse
Claire D. Coles, Gretchen Bandoli, Julie A. Kable, Miguel del Campo, Michael Suttie, Christina D. Chambers
Summary: There is a lack of consistency in the diagnosis of Fetal Alcohol Spectrum Disorder (FASD), leading to a small percentage of affected children being identified in clinical practice. The discrepancies may be due to differences in the operationalization of diagnostic criteria. By reanalyzing data from the COFASP study, it was found that three commonly used FASD diagnostic systems showed inconsistent identification of children in a community sample. These results suggest the need for a more empirically-based diagnostic schema.
ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH
(2023)
Letter
Rheumatology
Kerri Bertrand, Steven Rossi, Alan Wells, Brookie Best, Christina D. Chambers
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Pediatrics
Lars Bode, Kerri Bertrand, Julia A. Najera, Annalee Furst, Gordon Honerkamp-Smith, Adam D. Shandling, Christina D. Chambers, David Camerini, Joseph J. Campo
Summary: Breast milk from mothers infected with SARS-CoV-2 contains IgA and IgG antibodies that can provide passive immunity against the virus. The study found that there are differences in antibody recognition between mothers, and the antibodies in breast milk show diverse responses to SARS-CoV-2.
PEDIATRIC RESEARCH
(2023)
Article
Public, Environmental & Occupational Health
Erin Delker, Ann Kelly, Christina Chambers, Diana Johnson, Gretchen Bandoli
Summary: The study found that prenatal NSAID use was associated with small for gestational age (SGA) infants, but not with preterm birth. Particularly, NSAID exposure in the first trimester was most strongly associated with SGA.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
(2023)
Article
Rheumatology
Jennifer Strouse, Lena Sabih, Gretchen Bandoli, Rebecca Baer, Laura Jelliffe-Pawlowski, Christina Chambers, Kelli Ryckman, Namrata Singh
Summary: This study examined racial/ethnic disparities in preterm birth risk among women with autoimmune rheumatic diseases (ARDs) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) in a large cohort. Birth records linked to hospital discharge data were analyzed, and the relative risk of preterm birth was compared among different racial/ethnic groups, stratified by ARD type. The study found that disparities in preterm birth risk were higher for women with RA compared to SLE or the general population.
CLINICAL RHEUMATOLOGY
(2023)
Article
Dermatology
Alexa B. Kimball, Maurizio Podda, Afsaneh Alavi, Megan Miller, Yaung-Kaung Shen, Shu Li, Yan Xu, Chenglong Han, Steven Fakharzadeh, Ya-Wen Yang, Samuel DePrimo, Ernesto Munoz, Yanqing Chen, Thierry Passeron, Kim Papp
Summary: This study aimed to evaluate the effect of guselkumab on the treatment of hidradenitis suppurativa (HS). The results showed that although there were modest improvements in HiSCR in the guselkumab group compared to the placebo group at Week 16, statistical significance was not achieved. Numerically greater improvements in patient-reported outcomes were also observed in the guselkumab group. However, the overall findings do not support the efficacy of guselkumab in the treatment of HS.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Genetics & Heredity
Yan Ding, Mallory Owen, Jennie Le, Sergey Batalov, Kevin Chau, Yong Hyun Kwon, Lucita van der Kraan, Zaira Bezares-Orin, Zhanyang Zhu, Narayanan Veeraraghavan, Shareef Nahas, Matthew Bainbridge, Joe Gleeson, Rebecca J. Baer, Gretchen Bandoli, Christina Chambers, Stephen F. Kingsmore
Summary: Universal newborn screening (NBS) is a successful public health intervention, and archived dried bloodspots (DBS) collected for NBS can provide high-quality genomic DNA (gDNA) for population genomic studies without the need for PCR amplification. This pilot study demonstrates simple methods for gDNA extraction and whole genome sequencing (WGS) library preparation from DBS up to 20 years old, yielding WGS of sufficient quality and quantity for variant calling.
NPJ GENOMIC MEDICINE
(2023)
Article
Dermatology
Alexa B. Kimball, Errol P. Prens, Thierry Passeron, Emanual Maverakis, Irina Turchin, Stefan Beeck, Leonidas Drogaris, Ziqian Geng, Tianyu Zhan, Izabella Messina, Falk G. Bechara
Summary: This study evaluated the efficacy and safety of risankizumab in the treatment of moderate-to-severe hidradenitis suppurativa (HS). The results showed that risankizumab is not an effective treatment for moderate-to-severe HS.
DERMATOLOGY AND THERAPY
(2023)
Article
Medicine, General & Internal
Mallory J. Owen, Meredith S. Wright, Sergey Batalov, Yonghyun Kwon, Yan Ding, Kevin K. Chau, Shimul Chowdhury, Nathaly M. Sweeney, Elizabeth Kiernan, Andrew Richardson, Emily Batton, Rebecca J. Baer, Gretchen Bandoli, Joseph G. Gleeson, Matthew Bainbridge, Christina D. Chambers, Stephen F. Kingsmore
Summary: Understanding the association of single-locus genetic diseases with infant mortality is important for public health and research. A cohort study conducted in San Diego County found that single-locus genetic diseases were the most common identifiable cause of infant mortality, and early diagnosis and timely treatment may decrease infant mortality.
Article
Rheumatology
Rashmi Dhital, Monica Guma, Dilli R. Poudel, Christina Chambers, Kenneth Kalunian
Summary: Care of young adults with SLE is challenging due to major life transitions co-occurring with chronic healthcare needs. This study found that young adults with SLE had higher rates of serious infection-related hospitalization compared to adults with SLE and young adults without SLE. Race/ethnicity and comorbidities were associated with hospitalization in young adults with SLE.
LUPUS SCIENCE & MEDICINE
(2023)
Article
Immunology
Corey L. Snyder, Ruby S. Gibson, Martina L. Porter, Alexa B. Kimball
Summary: Secukinumab, an IL-17A inhibitor, has shown promising results in the treatment of hidradenitis suppurativa. This article reviews its mechanism of action, clinical efficacy, and safety data. Hidradenitis suppurativa is a chronic skin disorder characterized by painful bumps, tunnels, and scarring. Tnf-alpha inhibitor adalimumab is currently the only FDA-approved medication for this condition.
